UFPG
ALNY icon

United Financial Planning Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

United Financial Planning Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32K Hold
21
– – ﹤0.01% 333
2026
Q1 		$6.95K Buy
21
+17
+425% +$5.79K ﹤0.01% 266
2025
Q4 		$1.59K Buy
+4
New +$1.77K ﹤0.01% 343

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

United Financial Planning Group's ALNY Position: Q2 2026 in Review

United Financial Planning Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 21 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

United Financial Planning Group first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.95K in Q1 2026. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • United Financial Planning Group held 21 shares of Alnylam Pharmaceuticals worth $6.32K as of Q2 2026.
  • United Financial Planning Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of United Financial Planning Group's portfolio in Q2 2026, its #333 holding.
  • United Financial Planning Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • United Financial Planning Group's Alnylam Pharmaceuticals position peaked at $6.95K in Q1 2026.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on United Financial Planning Group's 13F filing for Q2 2026, filed 6 Aug 2026.